Leonardo DRS has dropped 21% over the past month to $38.54 — a sharper drawdown than most of its defense peers — while the fundamental case remains intact and short sellers are actually retreating.
The sector context sharpens the contrast. Close peers RTX and LMT finished the week roughly flat, down less than 1%. LHX and NOC slipped around 1–1.5%. DRS's 5.3% weekly loss stands out as the weakest performance in the peer group, suggesting the selling is company-specific rather than a broad defense-sector rotation. The stock is now trading more than 16 points below the Street's mean price target of $54.10, implying roughly 40% upside if analysts are right — a gap that looks wide even by defense-sector standards.
Positioning tells a low-conviction story on the short side. Short interest has declined 8.5% over the week to just 1.05% of free float — one of the smaller short positions in the sector. Borrow cost runs at 0.43%, barely above the risk-free floor, and availability is essentially unconstrained at 9,999%, meaning shares to borrow vastly outnumber the amount already lent. The put/call ratio sits at 0.32, barely half a standard deviation above its 20-day mean of 0.31 and nowhere near the 52-week defensive extreme of 0.64. None of these readings suggest a market leaning hard against the stock; if anything, they point to an orderly unwind rather than a panicked short build.
The Street's bias remains constructive, though the most recent activity is not particularly fresh. JP Morgan's Seth Seifman raised his target to $53 at end of July, maintaining Neutral — acknowledging progress while stopping short of endorsing the stock. BofA Securities carried a Buy with a $55 target from March, and Canaccord held its Buy at $54 from May. The bulls point to a record $8.9 billion backlog, 24% growth in Advanced Sensing funded bookings, and 34% top-line growth in Integrated Mission Systems. Bears flag EBITDA margins compressed to 12.2%, rising R&D costs, and Germanium supply-chain pressure that management is still working to resolve. At a trailing P/E near 27x and EV/EBITDA of roughly 17.9x — both down meaningfully over the past 30 days as the price has fallen — valuation has become more attractive in absolute terms, even if the margin headwinds are unresolved. Factor scores corroborate the mixed picture: EPS surprise ranks in the 77th percentile and dividend score in the 88th, but forward earnings growth momentum ranks only in the 26th percentile, pointing to modest near-term estimate revision activity.
Insider activity adds a note of caution. The CEO sold 36,471 shares in mid-June at $45.67 for proceeds of roughly $1.7 million. The CFO followed with a sale in early June. An EVP sold twice in June and August. These are not enormous in size relative to the company, but the cluster of C-suite sales happened with the stock well above current levels — sellers who exited near $45–$50 have so far been correct. Net insider activity over 90 days shows a positive figure in shares, but that is largely explained by director award grants rather than open-market purchases, which offers limited conviction on the bullish read.
The ORTEX short score has drifted lower all week, from 37.0 on August 17 to 35.1 on August 27, reflecting the shrinking short base rather than any fresh bearish catalyst. Next earnings are pencilled in for October 30. The last two prints each produced a negative one-day reaction — down 0.6% and 1.1% respectively — with muted five-day follow-through. The October release will therefore be less about whether the backlog story holds and more about whether management can show margin recovery alongside the top-line momentum it has already demonstrated.
See the live data behind this article on ORTEX.
Open DRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
